8月8日消息--环球医学据悉，美国食品和药品监督管理局已批准孟鲁司特钠咀嚼片的第一个仿制药，用于治疗儿童和成人的哮喘症状及室内和室外过敏症状。

尽管审理部门警告说，孟鲁司特钠应该被仅用于治疗哮喘突然发作，因为其导致严重的副作用，FDA表示，孟鲁司特钠药的仿制药将有助于为患者提供更多的选择，。

药物相关的一些常见的副作用包括抑郁症、情绪波动、攻击性和幻觉。（环球医学）

原文

FDA Approves Generic Singulair

The first generic forms of Singulair have been approved by the US Food and Drug Administration for treating children and adults with asthma symptoms and indoor and outdoor allergies symptoms.

The FDA said that generic versions of montelukast sodium drug will help provide more options for patients though the agency warned that it should be used to treat a sudden asthma attack as some of the side effects of montelukast were serious.

Some of the common side effects associated with the drug includes depression, mood swings, aggressions and hallucinations

          相关链接：http://www.medindia.net/news/fda-approves-generic-singulair-105170-1.htm

        版权声明：本文系环球医学独家稿件，版权为环球医学所有。欢迎转载，请务必注明出处（环球医学网），否则必将追究法律责任。